Arbutus Biopharma
ABUS
177 hedge funds and large institutions have $675M invested in Arbutus Biopharma in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 63 increasing their positions, 41 reducing their positions, and 22 closing their positions.
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
54% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 41
22% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $968K
8% more capital invested
Capital invested by funds: $625M → $675M (+$49.4M)
6% more funds holding
Funds holding: 167 → 177 (+10)
0.08% more ownership
Funds ownership: 71.1% → 71.18% (+0.08%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$10.6M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$7.19M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.7M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$4.23M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$36M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$8.19M |
| 4 |
Millennium Management
New York
|
-$2.89M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$2.53M |
ABUS Hedge Fund Activity: Q2 2026 in Review
177 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2026, worth a combined $675M — up 7.9% from $625M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ABUS positions and 22 closed out — a net gain of 12 holders — while 63 added to existing stakes and 41 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $10.6M. The largest seller was Morgan Stanley, cutting an estimated $36M.
- 177 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2026, up from 167 in Q1 2026.
- Funds reported $675M of Arbutus Biopharma stock for Q2 2026, up 7.9% quarter-over-quarter.
- 34 funds opened new Arbutus Biopharma positions in Q2 2026 and 22 closed out, a net change of +12 holders.
- The largest Arbutus Biopharma buyer in Q2 2026 was Goldman Sachs, an estimated $10.6M added.
- The largest Arbutus Biopharma seller in Q2 2026 was Morgan Stanley, an estimated $36M sold.
Based on aggregated 13F filings for Q2 2026.